PI3K/Akt/mTOR Signaling

The PI3K/Akt/mTOR signaling pathway is a key regulator in growth, survival, cell cycle proliferation, protein synthesis and glucose metabolism. Growth factors, hormones, and cytokines can activate this pathway by binding their cognate receptor tyrosine kinase (RTK), cytokine receptor, or GPCR, resulting in the activation of lipid kinase PI3K which produces PIP3 at the plasma membrane.
The binding of PIP3 translocates Akt to cell membranes, enables Akt activation through phosphorylation at Thr308 mediated by phosphoinositide dependent kinase 1 (PDK1). In addition, Akt is phosphorylated at Ser473 by the mTOR-rictor complex, mTORC2. PTEN is a negative regulator of Akt signaling that reverses the function of PI3K by removing 3’-phosphate groups. Akt activity is also negatively regulated by the phosphatases PP2A and PHLPP. Akt propagates its signal to affect DNA transcription, cell cycle and apoptosis. Akt can activate mTOR directly by phosphorylation or indirectly, by phosphorylation and inactivation of mTOR inhibitor TSC2 and PRAS40. Together these mechanisms stimulate cell growth and G1 cell cycle progression through signaling via p70 S6 Kinase and inhibition of 4E-BP1. Defects in PI3K/AKT/mTOR signaling are implicated in cancer, diabetes and cardiovascular disease etc.
-
B2187 PIK-293Summary: PI3K inhibitor -
B2186 GSK2636771Target: PI3KSummary: PIK3 inhibitor -
B2183 CH5132799Summary: Class I PI3K inhibitor -
B2182 CAY10505Summary: Potent PI3Kγ inhibitor -
B2181 AS-604850Summary: PI3Kγ inhibitor,selective and ATP-competitve -
B2180 AS-252424Target: Akt|PI3KSummary: PI3Kγ inhibitor,novel and potent -
B2178 BAY 80-6946 (Copanlisib)1 CitationTarget: PI3KSummary: PI3K inhibitor -
B2177 TG100713Target: PI3KSummary: pan-PI3K inhibitor -
B2176 GSK1059615Target: PI3K|mTORSummary: PI3K and mTOR inhibitor,potent and reversible -
B2172 PP121Target: mTOR|Eph Receptors|VEGFR|PDGFR|Bcr-Abl|Src|DNA-PK|P110|HckSummary: Dual inhibitor of tyrosine and phosphoinositide kinases
